Carrie House, PhDSan Diego State University Research FoundationSan Diego, CA Role of Macrophages in the Development of Drug-Resistant Ovarian Cancer Stem Cells Following Chemotherapy Ovarian cancer is the deadliest gynecological cancer in the United States and is associated with a high rate of recurrence. Unfortunately, tumors that grow back stop responding to chemotherapy and become […]
Read More
Targeting STAT3 Signaling for Immune Checkpoint Blockade to Augment PARP Inhibitor Therapy in BRCA-Mutated Ovarian Cancer PARP inhibitors and immune checkpoint inhibitors are two promising new therapies for ovarian cancer patients who have mutations in the BRCA gene. BRCA-mutated ovarian cancer cells produce a protein called PD-L1 to avoid being recognized and killed by immune […]
Read More
Development of RAD51 degraders for ovarian cancer treatment PARP inhibitor drugs have had a major impact on the clinical treatment of ovarian cancer in recent years, but they do not work in all patients. Many tumors have genetic mutations that make the tumor unable to repair damage to its DNA. PARP inhibitors exploit this fact […]
Read More
Dipanjan Chowdhury, PhDDana-Farber Cancer Institute OC130658: Noncoding RNAs as Prognostic and Predictive Biomarkers in BRCA 1/2-Mutated and Wildtype Epithelial Ovarian Cancer Patients with epithelial ovarian cancer that carry BRCA1 or BRCA2 mutations can successfully be treated with platinum chemotherapy and PARP inhibitors because the BRCA1/2 mutations cause a defect in DNA repair. This allows the […]
Read More
Yunfei Wen, PhDUniversity of Texas MD Anderson Cancer Center2014 Margaret Sherman Bridge Funding Award Promoting Autophagic Catabolism in Chemoresistant Ovarian Cancer Cells routinely remove unnecessary or damaged cellular components by a process called autophagy in which small pockets of enzymes inside cells degrade those components and recycle them for other uses. Dr. Wen has discovered […]
Read More
Yang Yang-Hartwich, PhDYale University2015 Cookie Laughlin Bridge Funding Award Targeting p53-regulated Twist1 Degradation to Inhibit Ovarian Cancer Metastasis Metastasis is a hallmark of advanced high-grade serous ovarian carcinoma. Turning off the ability of ovarian cancer to spread or metastasize to other places in the body would provide better therapies and prevent recurrence. The objective of […]
Read More
Cheng Wang, PhDUniversity of Nebraska Medical Center2015 Barbara Learned Bridge Funding Award The Hippo/YAP Signaling Pathway in Ovarian High Grade Serous Carcinoma Knowing where and how ovarian cancer starts will lead to earlier detection and better therapies. Recent studies have identified the fallopian tube secretory epithelial cell as the origin for high-grade serous ovarian carcinoma, […]
Read More
Paul Campagnola, PhDUniversity of Wisconsin – Madison2015 Joanie Warner Bridge Funding Award Quantitative Assessment of the Role of Collagen Alterations in Ovarian Cancer High grade serous ovarian cancer arises from fallopian tube cells that migrate and implant on the ovaries, then subsequently metastasize to other sites in the body. The 3-dimensional composition and architecture of […]
Read More
Jia Liu, PhDUniversity of Arkansas for Medical Science2016 Cookie Laughlin Bridge Funding Award Myxoma Virus in Combination with Chemotherapy for Treatment of Ovarian Cancer Resistance to chemotherapy occurs in the vast majority of women diagnosed with ovarian cancer and is a major barrier for effective treatment of the disease. Additionally, cells called tumor-associated macrophages (TAMs) […]
Read More
Manish Patankar, PhDUniversity of Wisconsin2016 Lynda’s Fund Bridge Award Identifying ovarian cancer biomarkers though lineage specific assessment of immune cell transcriptome Several decades of work have focused on the liquid portion of blood samples in order to identify biomarkers for early detection of ovarian cancer. Unfortunately, no biomarkers yet identified have proved useful for revolutionizing […]
Read More